Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00375934 · ClinicalTrials.gov registry record · Phase 3

Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery

A Phase 3 study of Pain, Postoperative, sponsored by Xanodyne Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
200
Enrollment target
4
Study locations

NCT00375934 is a Phase 3 study of Pain, Postoperative that has completed, run by Xanodyne Pharmaceuticals. The registered enrollment target is 200 participants, below the 271-participant average among 108 other Pain, Postoperative trials with a reported enrollment target (26% lower). The trial reports 4 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00375934, a Phase 3 study of Pain, Postoperative, has completed, sponsored by Xanodyne Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
200 participants
Enrollment target
4
Study locations

Study Summary

A multicenter study to evaluate the analgesic efficacy of XP21L in subjects with pain following bunionectomy surgery.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG diclofenac potassium (XP21L)

Study Locations (4)

Texas

  • Investigative Site - Austin
  • Investigative Site - Houston
  • Investigative Site - San Marcos

Utah

  • Investigative Site - Salt Lake City

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2006-09
Phase Phase 3

Sponsor

Xanodyne Pharmaceuticals

4 total trials

What the Registry Record Tells You About NCT00375934

The ClinicalTrials.gov registry entry for NCT00375934 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 271-participant average among 108 other Pain, Postoperative trials with a reported enrollment target (26% lower). The listed sponsor is Xanodyne Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pain, Postoperative appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00375934 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Texas, Utah.

Frequently Asked Questions

What is clinical trial NCT00375934 about?

NCT00375934 is a clinical study titled "Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery". A multicenter study to evaluate the analgesic efficacy of XP21L in subjects with pain following bunionectomy surgery.

What is the current status of trial NCT00375934?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2006-09.

What conditions does trial NCT00375934 study?

This clinical trial studies the following conditions: Pain, Postoperative.

What interventions are being tested in trial NCT00375934?

The interventions under investigation include: Placebo (DRUG), diclofenac potassium (XP21L) (DRUG).

Who is sponsoring clinical trial NCT00375934?

This trial is sponsored by Xanodyne Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00375934 being conducted?

This trial has 4 study locations across Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain, Postoperative

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.